PRVBライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2023 @ 05:00):

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases...

Stats
本日の出来高	9.12M
平均出来高	2.84M
時価総額	2.38B
EPS	$0 ( 2024-03-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.43
ATR14	$0.594 (2.38%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Sessa Capital (master), L.p.	Sell	15 567 497	Common Stock
2023-04-27	Wysenski Nancy	Sell	128 981	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	22 200	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	23 000	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	33 000	Option to Purchase Common Stock

INSIDER POWER
-62.73
Last 100 transactions
Buy: 11 373 023 \| Sell: 48 540 195

ボリューム相関

長: 0.34 (neutral)

短: 0.37 (neutral)

Signal:(80.187) Neutral

Provention Bio Inc 相関

10 最も正の相関
KRBP	0.886
RICO	0.879
NETE	0.825
MMAC	0.812
LWAC	0.809

10 最も負の相関
SQBG	-0.875
TCAC	-0.873
TCACU	-0.869
RMRM	-0.85
SVAC	-0.82
TLGT	-0.819

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Provention Bio Inc 相関 - 通貨/商品

0.13
( neutral )

0.68
( moderate )

0.57
( weak )

0.45
( neutral )

-0.83
( strong negative )

-0.14
( neutral )

Provention Bio Inc 財務諸表

Annual	2022
収益:	$12.90M
総利益:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2022
収益:	$12.90M
総利益:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2021
収益:	$1.40M
総利益:	$0.00 (0.00 %)
EPS:	$-1.810

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.880

Financial Reports:

No articles found.

Provention Bio Inc

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.